低氧性肺动脉高压病理机制与治疗药物研究进展  

Research progress on mechanisms and therapeutic drugs of hypoxic pulmonary hypertension

作　　者：王建美 袁天翊[1] 高丽[2] 秦雪梅[2] 杜冠华[1] WANG Jian-mei;YUAN Tian-yi;GAO Li;QIN Xue-mei;DU Guan-hua(Beijing Key Lab of Drug Target Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China;Modern Research Center for Traditional Chinese Medicine,Shanxi University,Taiyuan 030006,China)

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京市药物靶点研究与新药筛选重点实验室,北京100050 [2]山西大学中医药现代研究中心,山西太原030006

出　　处：《中国药理学通报》2022年第9期1281-1288,共8页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金面上项目(No 82073853);中国医学科学院医学与健康科技创新工程-重大协同创新项目(No 2021-I2M-1-005)。

摘　　要：低氧性肺动脉高压(hypoxic pulmonary hypertension, HPH)是由缺氧引起的复杂心肺疾病。其病理机制复杂,具有较高的致残致死率。目前,临床上暂无针对HPH治疗的药物,主要依赖基于肺动脉血管舒张的抗肺动脉高压药物,包括前列腺素I2受体激动剂、内皮素受体拮抗剂和磷酸二酯酶-5抑制剂,但疗效不能满足临床需求,研发针对HPH的治疗药物具有重要意义。该文对HPH的病理生理机制、药物研发现状进行综述,以期为HPH治疗药物的发现提供思路。Hypoxic pulmonary hypertension (HPH) is a complex cardiopulmonary disease caused by hypoxia.The pathological mechanism of HPH is complex,and it has a high mortality rate of disability.Clinically the drug of treatment for HPH is unspecialized,mainly relying on traditional vasomotor drugs,including prostaglandin I2 receptor agonists,endothelin receptor antagonists and phosphodiesterase-5 inhibitors,but their efficacy cannot be achieved.To meet the clinical need,it is of great significance to develop targeted anti-HPH drugs.To provide ideas for the discovery of HPH treatment drugs,the pathophysiological mechanism of HPH and the current status of drug development are reviewed in the paper.

关 键 词：低氧性肺动脉高压 肺动脉收缩 肺动脉重塑 临床用药 试验药物 药物靶点 

分 类 号：R322.12[医药卫生—人体解剖和组织胚胎学] R442.9[医药卫生—基础医学] R544R544.05R845.22